Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

Clin Exp Allergy. 2023 May;53(5):586-589. doi: 10.1111/cea.14305. Epub 2023 Mar 16.

Authors

Roselie Achten¹, Coco Dekkers¹, Daphne Bakker¹, Chantal van Luijk², Marlies de Graaf¹, Femke van Wijk³, Joke de Boer², Marjolein de Bruin-Weller¹, Judith Thijs¹

Affiliations

¹ Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.
² Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands.
³ Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

PMID: 36924265
DOI: 10.1111/cea.14305

No abstract available

Keywords: atopic dermatitis; autoimmunity; basic mechanisms; dermatology; ocular allergy.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Dermatitis, Atopic* / drug therapy
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
tralokinumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal